NCT03582475View on ClinicalTrials.gov

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 11, 2019

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
Bladder Small Cell Neuroendocrine CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaProstate Carcinoma Metastatic in the BoneProstate Neuroendocrine NeoplasmProstate Small Cell CarcinomaStage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8Stage III Prostate Cancer AJCC v8Stage III Urethral Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Stage IVA Bladder Cancer AJCC v8Stage IVB Bladder Cancer AJCC v8Ureter Small Cell CarcinomaUrothelial Carcinoma
Interventions
DRUG

Carboplatin

Given IV

DRUG

Cisplatin

Given IV

DRUG

Docetaxel

Given IV

DRUG

Etoposide

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER